Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: Clinical and immune responses in 35 patients

Blood

Volumn 99, Issue 5, 2002, Pages 1517-1526

  Timmerman, John M ^a   Czerwinski, Debra K ^a   Davis, Thomas A ^a   Hsu, Frank J ^a   Benike, Claudia ^a   Hao, Zheng Mei ^a   Taidi, Behnaz ^a   Rajapaksa, Ranjani ^a   Caspar, Clemens B ^a   Okada, Craig Y ^a   Van Beckhoven, Adrienne ^a   Liles, Tina Marie ^a   Engleman, Edgar G ^a   Levy, Ronald ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; IMMUNOGLOBULIN G; IMMUNOGLOBULIN IDIOTYPE; KEYHOLE LIMPET HEMOCYANIN; TUMOR VACCINE;

ACTIVE IMMUNIZATION; ADULT; ARTICLE; B CELL LYMPHOMA; CELLULAR IMMUNITY; CLINICAL ARTICLE; DENDRITIC CELL; FEMALE; FOLLICULAR LYMPHOMA; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOGLOBULIN PRODUCTION; IMMUNOTHERAPY; MALE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; T LYMPHOCYTE; TUMOR REGRESSION; VACCINATION;

EID: 0036493712     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V99.5.1517     Document Type: Article

References (56)

1. Natural history of and therapy for the indolent non-Hodgkin's lymphomas
2. Treatment of B-cell lymphoma with monoclonal antiidiotype antibody
3. Shared idiotypes expressed by human B-cell lymphomas
4. Anti-idiotypic mechanisms involved in suppression of a mouse B cell lymphoma, BCL1
5. Idiotype vaccination against murine B cell lymphoma: Humoral and cellular responses elicited by tumor-derived immunoglobulin M and its molecular subunits
6. Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors
7. Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma: Long-term results of a clinical trial
8. Naive idiotype-specific CD4+ T cells and immunosurveillance of B-cell tumors
9. Recognition of an immunoglobulin VH epitope by influenza virus-specific class I major histocompatibility complex-restricted cytolytic T lymphocytes
10. Induction of syngeneic cytotoxic T lymphocytes against a B cell tumor, II: Characterization of anti-idiotypic CTL lines and clones
11. Induction of humoral and cellular anti-idiotypic immunity by intradermal injection of naked DNA encoding a human variable region gene sequence of an immunoglobulin heavy chain in a B cell malignancy
12. Stimulation of cytotoxic T cells against idiotype immunoglobulin of malignant lymphoma with protein-pulsed or idiotype-transduced dendritic cells
13. Idiotype vaccination against murine B cell lymphoma: Humoral and cellular requirements for the full expression of antitumor immunity
14. Idiotypic vaccination as a treatment for a B cell lymphoma
15. Protective and cellular immune responses to idiotypic determinants on cells from a spontaneous lymphoma of NZB-NZW F1 mice
16. Vaccination with syngeneic, lymphoma-derived immunoglobulin idiotype combined with granulocyte/macrophage colony-stimulating factor primes mice for a protective T-cell response
17. Immunotherapy of established murine B cell lymphoma: Combination of idiotype immunization and cyclophosphamide
18. Dendritic cells and the control of immunity
19. Immunobiology of dendritic cells
20. Dendritic cell vaccines for cancer immunotherapy
21. Murine dendritic cells pulsed in vitro with tumor antigen induce tumor resistance in vivo
22. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells
23. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells
24. Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma
25. Phase II prostate cancer vaccine trial: Report of a study involving 37 patients with disease recurrence following primary treatment
26. Infusion of dendritic cells pulsed with HLA-A2-specific prostate-specific membrane antigen peptides: A phase II prostate cancer vaccine trial involving patients with hormone-refractory metastatic disease
27. Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids
28. Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy
29. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas: NCI Sponsored international Working Group
30. Use of family specific leader region primers for PCR amplification of the human heavy chain variable region gene repertoire
31. TCR vaccines for active immunotherapy of T cell malignancies
32. Generation of antigen-specific CD4+ T cell lines from naive precursors
33. Generation of antigen-specific CD8+ CTLs from naive precursors
34. Autologous tumor infiltrating T cells cytotoxic for follicular lymphoma cells can be expanded in vitro
35. Lymphoma regression induced by monoclonal anti-idiotypic antibodies correlates with their ability to induce Ig signal transduction and is not prevented by tumor expression of high levels of bcl-2 protein
36. Linkage of foreign carrier protein to a self-tumor antigen enhances the immunogenicity of a pulsed dendritic cell vaccine
37. The role of tyrosine protein phosphorylation in lymphocyte activation
38. Anti-idiotype antibodies can induce long-term complete remissions in non-Hodgkin's lymphoma without eradicating the malignant clone
39. Complete molecular remissions induced by patientspecific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma
40. DNA vaccination against the idiotype of a murine B cell lymphoma: Mechanism of tumor protection
41. Antiimmunoglobulins induce death by apoptosis in WEHI-231 B lymphoma cells
42. Anti-immunoglobulin antibodies induce apoptosis in immature B cell lymphomas
43. New approach to classifying non-Hodgkin's lymphomas: Clinical features of the major histologic subtypes: Non-Hodgkin's Lymphoma Classification Project
44. The distinct surface of human blood dendritic cells, as observed after an improved isolation method
45. Generation of large numbers of fully mature and stable dendritic cells from leukapheresis products for clinical application
46. Immune and clinical responses after vaccination of patients with metastatic melanoma with CD34+ HPC-derived dendritic cells
47. In vivo generation of human dendritic cell subsets by Flt3 ligand
48. A monocyte conditioned medium is more effective than defined cytokines in mediating the terminal maturation of human dendritic cells
49. Optimization of the sequence of antigen loading and CD40-ligand-induced maturation of dendritic cells
50. CpG DNA: A potent signal for growth, activation, and maturation of human dendritic cells
51. Active immunotherapy of patients with lymphoma with sequential dendritic cell and protein/adjuvant idiotype vaccines
52. A phase 1/11 trial to evaluate the immunogenicity of recombinant idiotype protein vaccines for the treatment of non-Hodgkin's lymphoma (NHL)
53. Idiotype-encoding recombinant adenoviruses provide protective immunity against murine B-cell lymphomas
54. Rapid production of specific vaccines for lymphoma by expression of the tumor-derived single-chain Fv epitopes in tobacco plants
55. DNA vaccines with single-chain Fv fused to fragment C of tetanus toxin induce protective immunity against lymphoma and myeloma
56. Rapid expression cloning of human immunoglobulin Fab fragments for the analysis of antigen specificity of B cell lymphomas and anti-idiotype lymphoma vaccination